EWTX · Edgewise Therapeutics, Inc.
$40.84
-3.00% last session
End-of-day data · updated 2026-07-28
Market cap
$4B
Enterprise value
$4B
Trailing P/E
—
Forward P/E
-28.2
Dividend yield
—
Beta
0.28
Avg volume
1M
Employees
0K
2D change
—
5D change
5.88%
10D change
4.63%
30D change
0.34%
60D change
21.78%
MTD change
6.26%
YTD change
67.64%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — EWTX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-20
Latest call per bank · past 12 months
RBC Capital
Outperform$59.00
+44.5% vs priceGoldman Sachs
Neutral$32.00
-21.6% vs priceJP Morgan
Overweight$45.00
+10.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-20 | Evercore ISI Group | Maintains | Outperform | $45.00 → $55.00 |
| 2026-07-09 | Oppenheimer | Initiates | Outperform | $0.00 → $51.00 |
| 2026-07-06 | Guggenheim | Maintains | Buy | $41.00 → $51.00 |
| 2026-06-17 | RBC Capital | Maintains | Outperform | $48.00 → $59.00 |
| 2026-06-17 | Goldman Sachs | Maintains | Neutral | $20.00 → $32.00 |
| 2026-06-16 | HC Wainwright & Co. | Reiterates | Buy | $45.00 |
| 2026-06-02 | HC Wainwright & Co. | Maintains | Buy | $42.00 → $45.00 |
| 2026-06-02 | RBC Capital | Maintains | Outperform | $50.00 → $48.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 52 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 7.1% above the 50-day MA ($37.66).
- Price vs 200-day MA: Trading 38.1% above the 200-day MA ($29.22).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.39) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($12.68) and high ($48.35).
EWTX Price Chart
Loading chart for EWTX…
Fundamentals
About Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.